We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DEMANT:OMXCOPDemant A/S Analysis

Data as of 2026-06-12 - not real-time

DKK 251.20

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Demant A/S is trading well above its 20‑day and 50‑day moving averages, reflecting a bullish price trend, yet the MACD histogram has turned negative, signaling emerging bearish momentum. The RSI sits in the high‑40s% range, indicating the stock is approaching overbought conditions. Recent earnings commentary highlights 6% organic revenue growth, driven by double‑digit gains in hearing aids and a successful new product launch, reinforcing the company's strong operating margins. However, the discounted cash flow model suggests a fair value far below the current market price, and the balance sheet shows a very high debt‑to‑equity ratio, raising concerns about financial leverage. With increasing volume and an “Extreme Greed” sentiment index, short‑term upside may be limited while the long‑term outlook hinges on sustained growth and debt reduction.
Overall, the stock presents a mixed picture: robust fundamentals and market leadership are tempered by valuation pressure, elevated leverage, and technical signs of potential pullback.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price is near resistance with bullish trend but MACD shows early bearish divergence
  • RSI approaching overbought territory
  • Recent earnings beat supports near‑term confidence

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Consistent organic revenue growth and strong hearing‑aid segment
  • Expansion of executive leadership team signals strategic focus
  • Valuation remains above fair value, creating a cushion for potential correction

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High debt‑to‑equity ratio limits financial flexibility
  • No dividend payout reduces income appeal
  • Sustainable competitive advantage in hearing‑care offsets valuation concerns

Key Metrics & Analysis

Financial Health

Revenue Growth3.40%
Profit Margin6.73%
P/E Ratio22.4
ROE24.20%
ROA6.93%
Debt/Equity211.59
P/B Ratio5.4
Op. Cash FlowDKK4.0B
Free Cash FlowDKK3.3B
Industry P/E24.8

Technical Analysis

TrendBullish
RSI62.8
SupportDKK 226.20
ResistanceDKK 265.00
MA 20DKK 245.22
MA 50DKK 222.48
MA 200DKK 218.89
MACDBearish
VolumeIncreasing
Fear & Greed Index89.86

Valuation

Fair ValueDKK 145.13
Target PriceDKK 247.68
Upside/Downside-1.40%
GradeOvervalued
TypeBlend

Risk Assessment

Beta0.52
Volatility46.88%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.